Artificial Intelligence Triumphs in World’s Most Sophisticated Autonomous Drone Race in Abu Dhabi
The Abu Dhabi Autonomous Racing League (A2RL), part of the Advanced Technology Research Council (ATRC), in collaboration with the Drone Champions League (DCL), concluded the inaugural A2RL x DCL Autonomous Drone Championship in the Middle East, at ADNEC Marina Hall, Abu Dhabi, UAE. In a major breakthrough for autonomous flight and aerial robotics, Team MavLab’s AI drone outpaced a world-leading human pilot to win the AI vs Human Challenge. The head-to-head duel was the most complex ever staged, featuring finalists from the DCL Falcon Cup—some of the top drone pilots in the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250416147445/en/
Artificial Intelligence Triumphs in World’s Most Sophisticated Autonomous Drone Race in Abu Dhabi (Photo: AETOSWire)
Over two high-intensity days, 14 international teams qualified for the finals week, with the top four advancing to compete across multiple challenging race formats. Teams from the UAE, Netherlands, Austria, South Korea, the Czech Republic, Mexico, Turkey, China, Spain, Canada and the USA represented a mix of university labs, research institutes, and startup innovators.
Each team raced a standardized drone equipped with the compact yet powerful NVIDIA Jetson Orin NX computing module, a forward-facing camera, and an inertial measurement unit (IMU) for onboard perception and control. With no human input, the drones relied entirely on real-time processing and AI-driven decision-making to reach speeds exceeding 150 km/h through a complex race environment.
The course design pushed the boundaries of perception-based autonomy—featuring wide gate spacing, irregular lighting, and minimal visual markers. The use of rolling shutter cameras further heightened the difficulty, testing each team’s ability to deliver fast, stable performance under demanding conditions. This marked the first time an autonomous drone race of this scale and complexity was staged on such a visually sparse track, underscoring the ambition and technical challenge of the event.
Championship Highlights
- AI Grand Challenge Winner: MavLab (TU Delft) set the fastest time on the 170-meter course, completing two laps (22 gates) in just 17 seconds.
- AI vs Human Showdown Winner: MavLab’s autonomous drone outpaced top human pilot—in a landmark AI vs Human showdown.
- Multi-Autonomous Drone Race Winner: TII Racing emerged victorious in the multi-drone format, in a high-speed test of AI coordination and collision avoidance.
- Autonomous Drag Race Winner: MavLab (TU Delft) claimed victory in the world’s first AI-only drag race, demonstrating straight-line speed and control under high acceleration against the championship’s top teams.
“At ATRC, we believe innovation must be proven in the real world, not just promised,” said H.E. Faisal Al Bannai, Adviser to the UAE President for Strategic Research and Advanced Technology Affairs, and Secretary-General of ATRC. “A2RL is more than a race, it’s a global testbed for high-performance autonomy and reflects the UAE’s commitment to advancing AI, robotics, and next-gen mobility responsibly.”
“The future of flight doesn’t live in a lab—it lives on the racetrack,” said Stephane Timpano, CEO of ASPIRE, the hosting entity of the Abu Dhabi Autonomous Racing League. “What we saw this weekend brings us closer to scaling autonomous systems in everyday life.” Markus Stampfer, Executive Chairman of DCL,added:“We brought elite racing conditions to autonomous flight—and the AI rose to the challenge. This was a major leap for both sport and technology.”
Ecstatic after clinching three top titles, Christophe De Wagter, team principal of MavLab, shared, “Winning the AI Grand Challenge and the AI vs Human race is a huge milestone for our team. It validates years of research and experimentation in autonomous flight. To see our algorithms outperform in such a high-pressure environment and take home the largest share of the prize pool, is incredibly rewarding.”
The A2RL X DCL Drone STEM Program, designed in collaboration with UNICEF and under the supervision of the ATRC, has trained over 100 Emirati students this year. Over 60% earned the prestigious Trusted Operator Program certification and 24 achieved perfect scores, showcasing the cutting-edge aviation skills being developed as part of the program.
With the drone finale now in the books, all eyes turn to Season 2 of A2RL’s autonomous car racing series, set for Q4 2025 at Yas Marina Circuit in Abu Dhabi.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20250416147445/en/
Contacts
Thushara Mohanan
thushara.mohanan@tii.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Recognized in The Digital Transformation Services Landscape Report28.4.2025 13:06:00 EEST | Press release
Global IT firm FPT announced its inclusion in Forrester’s The Digital Transformation Services Landscape, Q2 2025. The report provides an overview of 35 digital transformation service providers and offers valuable insights into the current market dynamics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428400623/en/ FPT is recognized as a Notable Provider in the report which stated that transformation leaders can use digital transformation services to “articulate and orchestrate strategy-aligned transformation journeys; align tech modernization with people, organization, and culture change, and navigate transformation risks.” The report notes FPT's geographical focus in North America and Asia-Pacific, along with its industry focus in financial services, IT/Tech services, and manufacturing/production of industrial products. FPT’s suite of digital transformation services includes cutting-edge solutions in AI, cloud computing
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom